All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
  Â
Erbitux 500mg Injection
Prescription Required
Salt Composition : Cetuximab
Manufacturer : MERCK LTD
Origin of Medicine : United States of America
1 Vial(s) Of 5ml
PAP Information : Â Â Buy 1, Get 1 Free. Contact us for latest updates.
Program Overview: MERCK LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of Erbitux 500mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase two vials of Erbitux 500mg injection, and you will receive one free additional vial. Therefore, if eligible, you will have to pay only Rs.1,76,750 for three vials, which is Rs.58,917 per vial.
With MrMed's MRP discount of Rs.17,875 per vial and Merck’s PAP program, the overall savings is over 1 lakh 42 thousand rupees.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Erbitux Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Cetuximab 500mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Merck can avail of it without having to purchase the medication from MrMed.
Patient Assistance Programs
Program Overview: MERCK LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of Erbitux 500mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase two vials of Erbitux 500mg injection, and you will receive one free additional vial. Therefore, if eligible, you will have to pay only Rs.1,76,750 for three vials, which is Rs.58,917 per vial.
With MrMed's MRP discount of Rs.17,875 per vial and Merck’s PAP program, the overall savings is over 1 lakh 42 thousand rupees.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Erbitux Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Cetuximab 500mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Merck can avail of it without having to purchase the medication from MrMed.
Introduction to Erbitux 500mg Injection
Erbitux 500mg injection is an anticancer medication containing the active ingredient Cetuximab which belongs to the class of medicine called a monoclonal antibody. It is used to treat metastatic cancer of the large intestine either alone or with a combination of medicines. Additionally, it is also used to treat certain types of squamous cell cancer of the head and neck. Cancer is a condition in which cells multiply uncontrolled and abnormally. Â
Do not take an Erbitux 500mg injection if you are allergic to Cetuximab or any other ingredients of this medicine. This medicine is not recommended for children and adolescents. Inform your doctor if you had or have any heart, kidney, or lung disorders. Inform your doctor if you are allergic to red meat, tick bite or positive for antibodies; it makes a severe allergic reaction. Please tell your doctor if you have eye problems like blurred vision, red or severe dry eyes, or eye pain. Â
Your doctor will take a blood test to monitor your WBC count; because there is a chance of reducing WBC counts while taking this medicine with a combination of anticancer medicine (platinum-based therapy). Inform your doctor if you take Fluropyrimidine as an anticancer combination, as this medication can cause life-threatening heart problems. Do not breastfeed or drive while taking the Erbitux 500mg injection. Discuss the effective contraception method, as this medicine should not be used during pregnancy.
Uses of Erbitux 500mg Injection
- Metastatic colorectal cancer
- Squamous cell cancer head and neck
Therapeutic Effects of Erbitux 500mg Injection
Cetuximab binds to the protein called epidermal growth factor receptor (EFGR). As a result of this binding, cancer cells no longer receive the signal that the cells need for growth and development. Thus, this medication prevents cancer cells from growing.Â
Interaction of Erbitux 500mg Injection with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products. In particular, tell your doctor if you are taking medicines for blood pressure or other heart conditions. Certain medications may interact with Erbitux 500mg injection and reduce its effectiveness by causing undesirable side effects.Â
More Information about Erbitux 500mg Injection
- Store Erbitux 500mg injection in the refrigerator (2°C to 8°C)
- Do not freeze
- keep the injection away from the reach of children and pets.
- If you have missed any dosing appointments, inform your doctor and schedule immediately.
How to consume Erbitux 500mg Injection
It should only be administered by a trained doctor or nurse. Do not self-administer the injection. Before giving the Erbitux 500mg injection, you will be given other antiallergic medicine (pre-medication) to reduce the possible side effects. Your doctor will decide the dose and duration of your treatment based on the disease severity and other factors. It will be given as an intravenous infusion, and you will be monitored carefully for any unwanted side effects.Â
Safety Advices for Erbitux 500mg Injection
 Â
Pregnancy
 Â
Erbitux 500mg injection may cause harm to the unborn baby when administered to a pregnant woman. You need to tell your physician if you are pregnant or planning to get pregnant before taking this medicine.Â
 Â
Breast Feeding
 Â
It is unsafe to take an Erbitux 500mg injection if you are breastfeeding as it passes into breast milk. You need to tell your physician if you are breastfeeding before taking this medicine.Â
 Â
Lungs
  Erbitux 500mg injection can cause interstitial lung disease (ILD). So, inform your physician about any underlying lung disorders before consuming, as this medication should be used cautiously in lung disease patients. Consult your physician before taking this medicine.Â
 Â
Liver
  Inform your physician about any underlying liver disorders before taking the Erbitux 500mg injection, as this medication should be used cautiously in liver disease patients. Consult your physician before taking this medicine.Â
 Â
Alcohol
 ÂIt is unknown whether consuming alcohol while taking an Erbitux 500mg injection is safe. Please speak with your physician.
 Â
Driving
  Driving while taking Erbitux 500mg injection is unsafe because this medicine might cause dizziness and tiredness, so avoid driving and operating machinery during this treatment.
Side Effects of Erbitux 500mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.Â
Serious
- Infusion reactions (swelling of face, eyes, mouth, throat, or lips, difficulty breathing, wheezing, chest pain, fainting, or fever)
- Heart problems
- Blistering or peeling of skin
- Vision problems
Common
- Diarrhea, constipation
- Weight loss, poor appetite
- Nausea, vomiting
- Excessive growth of hair in the skin
- Low blood counts
- Difficulty breathing, cough
- Liver problems
- Infection
- Headache
- Weakness
- Skin rash
Word of Advice
Before starting the treatment with metastatic cancer, your doctor will take a test of your cells to detect whether your blood contains the normal or mutant form of RAS. If they contain, then Erbitux 500mg injection must not be received in combination with other anticancer treatments containing Oxaliplatin. It is not advised to use in children and adolescents. Consult your doctor immediately if you experience any cardiopulmonary-related symptoms. Do not freeze the medicine.Â
FAQs
Q 1. Does an Erbitux 500mg injection cure cancer?
Erbitux 500mg injection is not a cure for cancer; instead, it can help to slow down or restrict the growth and spread of cancer cells, which improves the quality of life of patients with certain types of cancer.
Q 2. How is Erbitux 500mg injection different from other cancer drugs?
Erbitux 500mg injection is a monoclonal antibody that targets a specific protein in cancer cells, while other cancer drugs may work differently.
Q 3. How often do patients need to receive Erbitux 500mg injection treatments?
The frequency of Erbitux 500mg injection treatments can vary depending on the type and stage of the cancer being treated, as well as other factors such as the patient's overall health.
Q 4. Can Erbitux 500mg injection be used in combination with other cancer treatments?
Yes, Erbitux 500mg injection is often used in combination with radiation therapy or chemotherapy to treat certain types of cancer.
Q 5. What is the difference between Erbitux 500mg injection and other cancer treatments?
Erbitux 500mg injection is a targeted therapy that specifically targets cancer cells with high levels of EGFR. It is different from chemotherapy and radiation therapy, which target both cancer and healthy cells.
Fact Box of Erbitux 500mg Injection
Molecule name: Cetuximab  | Therapeutic class: Antineoplastics |
Pharmacological class: Monoclonal antibody | Indications: 1. Metastatic cancer colorectal cancer 2. Squamous cell cancer head and neck |
References
- Merck Europe BV, Electronic medicines compendium (emc), [Revised on July 2019] [ Accessed on 22nd April 2023], https://www.medicines.org.uk/emc/product/317/pil
- Eli Lilly and Company, US Food and Drug Administration, [Revised on April 2019] [ Accessed on 22nd April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
- Richard M Goldberg; Cetuximab; Nature Reviews. Drug Discovery; Published on May 2005; Accessed on 22nd April 2023; https://pubmed.ncbi.nlm.nih.gov/15962524/
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
